Compare CUE & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CUE | NOTV |
|---|---|---|
| Founded | 2014 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 29.9M |
| IPO Year | 2018 | 1997 |
| Metric | CUE | NOTV |
|---|---|---|
| Price | $0.51 | $0.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.00 | $3.00 |
| AVG Volume (30 Days) | 363.2K | ★ 1.6M |
| Earning Date | 11-12-2025 | 12-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $7,100,000.00 | ★ $513,024,000.00 |
| Revenue This Year | $36.58 | $6.26 |
| Revenue Next Year | $32.10 | $45.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 4.54 |
| 52 Week Low | $0.51 | $0.66 |
| 52 Week High | $1.75 | $6.48 |
| Indicator | CUE | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 31.28 | 37.84 |
| Support Level | $0.55 | $0.79 |
| Resistance Level | $0.66 | $0.95 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 7.88 | 52.03 |
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.